4
Changes in Ownership
Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-23-016039
EVP & Chief Commercial Officer sold 3,664 shares at $45.25 ($165,796)
- EVP & Chief Commercial Officer acquired 24,663 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Harris Erik EVP & Chief Commercial Officer | 2023-03-01 | Grant or award | +2,663 | 38,823 | D: show line 1 in the form | ||
| Harris Erik EVP & Chief Commercial Officer | 2023-03-01 | Grant or award | +22,000 | 60,823 | D: show line 2 in the form | ||
| Harris Erik EVP & Chief Commercial Officer | 2023-03-01 | Sale | −3,664 | $45.25 | $165,796 | 57,344 | D: show line 3 in the form |
| Open-market sales · 3,664 sh · avg $45.25 · $165,796 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Harris Erik EVP & Chief Commercial Officer | 2023-03-01 | Grant or award · Stock Option (Right to Buy) | +39,400 | 39,400 | D: show line 4 in the form |
Loading xslF345X03/doc4.xml…